We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Rap4.5
Rapamycin Research
Mostly mechanism / observationalLimited safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Rapamycin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2009–2025 with a typical study size of 218 participants.
Based on 7 studies · 1 meta-analysis · 2 RCTs · 242 total participants
Confidence
Moderate
By outcome
Lifespan & aging (preclinical)
Mostly mechanism / observational7 studies
Immune function
Too few graded studies2 studies
Safety profile
Too few graded studies1 study
Steady research
1 study in the last 5 years · Latest meta-analysis: 2017
200920172025
1RCTn=218 · medium study2014
RAD001 (everolimus) enhanced the response to the influenza vaccine by about 20% at doses that were relatively well tolerated.
Mannick, Del Giudice, Lattanzi, Valiante, Praestgaard, Huang · Science translational medicine (2014)
Randomized, placebo-controlled trial of low-dose everolimus (RAD001) in elderly volunteers
Improved the antibody response to influenza vaccination by ~20% and reduced PD-1 exhaustion marker on CD4/CD8 T cells
The best human signal that mTOR inhibition can partially reverse immunosenescence